Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sichuan Haisco Pharmaceutical Co. Ltd. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, the portfolio has 1 pending office action. This figure shows a focused and limited scope of active prosecution at the present time. For a practitioner, this indicates that the company's immediate pharmaceutical patent strategy is centered on a single application.
The company's patent applications are being reviewed by a distinct examiner in a single art unit. This indicates that the pharmaceutical innovations are being processed through a single administrative path at the USPTO. MEJIAS, SAMANTHA LEE is the busiest examiner for this company. The concentration in a single art unit suggests a highly specialized technical review of the company's biopharmaceutical assets.
MEJIAS, SAMANTHA LEE is currently handling 1 busiest examiner pending office action. Since there is only a single pending action in total, the specific feedback from MEJIAS, SAMANTHA LEE will be the primary factor in the portfolio's immediate development. Practitioners should prepare responses that address the specific concerns of this examiner and the requirements of the art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEJIAS, SAMANTHA LEE | 1 | 46.7% | +40.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18006255 | SUSTAINED-RELEASE PHARMACEUTICAL FORMULATION OF FUSED TRICYCLIC ?-AMINO ACID DERIVATIVE AND PREPARATION METHOD THEREFOR | MEJIAS, SAMANTHA LEE | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18006255 | SUSTAINED-RELEASE PHARMACEUTICAL FORMULATION OF FUSED TRICYCLIC ?-AMINO ACID DERIVATIVE AND PREPARATION METHOD THEREFOR | MEJIAS, SAMANTHA LEE | 1618 | §103 | Final Rejection | — | Pending | Jan 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSichuan Haisco Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Samantha Lee Mejias has the most, with 1 of Sichuan Haisco Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
